Surface Oncology, Inc. [SURF]

Last updated: 31 jan 2023 @ 15:59
Share On:

1.54% $0.934


Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibody that inhibits CD39 enzymatic activity for the production of adenosine and the breakdown of adenosine triphosphate; SRF388 targeting interleukin 27; GSK4381562, an antibody targeting CD112R, an inhibitory protein expressed on natural killer and T cells; and SRF114 targeting the chemokine receptor CCR8...

Current Price $0.934
Today's Volume 143 289T
Average Volume 319 657T
Market Cap 56.56M
P/E 0
ATR14 $0 (0.00%)